18285-95-5

Upstream product

• 2067-33-6 5-bromopentanoic acid 

Downstream Products

• 43170-02-1 5'-(4-Methylbenzylseleno)-valeriansaeure 
• 34835-12-6 5-(4-Nitrobenzylseleno)valeriansaeure 
• 34835-31-9 5-(2,4-Dinitro-phenylselanyl)-pentanoic acid 
• 43170-04-3 5-(4'-Bromphenylseleno)-valeriansaeure 
• 7370-56-1 5-(benzylseleno)pentanoic acid 
• 53942-85-1 5-(β-Phenylethylseleno)-valeriansaeure 
• 34835-22-8 5-(4-Nitrophenylethylseleno)valeriansaeure 

Relevant academic research and scientific papers

Surface Modification Based on Diselenide Dynamic Chemistry: Towards Liquid Motion and Surface Bioconjugation

Surface modification is an important technique in fields, such as, self-cleaning, surface patterning, sensing, and detection. The diselenide bond was shown to be a dynamic covalent bond that can undergo a diselenide metathesis reaction simply under visible light irradiation. Herein we develop this diselenide dynamic chemistry into a versatile surface modification method with a fast response and reversibility. The diselenide bond could be modified onto various substrates, such as, PDMS, quartz, and ITO conductive film glass. Different functional diselenide molecules could then be immobilized onto the surface via diselenide metathesis reaction. We demonstrated that by using this modification method we could achieve liquid motion in a capillary tube under light illumination. We also show that this approach has the potential to serve as an efficient modification method for surface bioconjugation, which has practical applications in clinical usage.

Diselenide–Pemetrexed Assemblies for Combined Cancer Immuno-, Radio-, and Chemotherapies

Immunotherapy has emerged as a promising new approach for cancer treatment. However, clinically available drugs have been limited until recently, and the antitumor efficacy of most cancer immunotherapies still needs to be improved. Herein, we develop diselenide–pemetrexed assemblies that combine natural killer (NK) cell-based cancer immunotherapy with radiotherapy and chemotherapy in a single system. The assemblies are prepared by co-assembly between pemetrexed and cytosine-containing diselenide through hydrogen bonds. Under γ-radiation, the hydrogen bonds are cleaved, resulting in the release of pemetrexed. At the same time, diselenide can be oxidized to seleninic acid, which suppresses the expression of human leukocyte antigen E (HLA-E) in cancer cells, thus activating the immune response of NK cells. In this way, cancer immunotherapy is combined with radiotherapy and chemotherapy, providing a new strategy for cancer treatment.